Revance Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2013 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Revance Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2013 to Q4 2023.
  • Revance Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $496M, a 15.9% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $496M +$68.1M +15.9% Dec 31, 2023 10-K 2024-02-28
Q4 2022 $428M +$71.9M +20.2% Dec 31, 2022 10-K 2024-02-28
Q4 2021 $356M +$88.3M +33% Dec 31, 2021 10-K 2023-02-28
Q4 2020 $267M +$43.1M +19.2% Dec 31, 2020 10-K 2022-02-28
Q4 2019 $224M +$54.7M +32.3% Dec 31, 2019 10-K 2021-02-25
Q4 2018 $170M +$41.2M +32.1% Dec 31, 2018 10-K 2020-02-26
Q4 2017 $128M -$30.8M -19.4% Dec 31, 2017 10-K 2019-02-28
Q4 2016 $159M +$29.2M +22.5% Dec 31, 2016 10-K 2018-03-02
Q4 2015 $130M +$25.2M +24% Dec 31, 2015 10-K 2017-02-28
Q4 2014 $105M +$19.3M +22.5% Dec 31, 2014 10-K 2016-03-04
Q4 2013 $85.5M Dec 31, 2013 10-K 2015-03-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.